Control, Purification and Crystallization of Renin
Keywords:
Renin–Angiotensin System (RAS), Juxtaglomerular (JG) cells, Angiotensinogen(AOG), Renin inhibiton, Renin inhibitors, Angiotensin-Converting Enzyme Inhibitors (ACEIs), Angiotensin Receptor Blockers (ARBs)Abstract
The renin–angiotensin system (RAS) has an important role in the control of blood pressure, hypertension, diabetes, and in the regulation of salt and volume homeostasis of organisms as well as in the heart failure, and other related renal dysfunctions. Renin is the main protease enzyme of the RAS. In kidney, Juxtaglomerular (JG) cells are most important site for renin production. Renin act on Angiotensinogen (AOG) and cleave Angiotensin I and form different Angiotensins-ANG II, ANG 1-7, ANG 1-9 using Angiotensin converting enzyme (ACE) and Angiotensin receptors (AT-R). RAS inhibition using β-Blockers, Angiotensin-Converting Enzyme Inhibitors (ACEIs), Angiotensin Receptor Blockers (ARBs), Direct Renin Inhibitors are proven important for the study of prevention of several renal diseases and cardiovascular diseases. Additionally, several drugs such as vitamin D receptor activators, endothelin antagonists, Aldosterone antagonists, or monocyte chemotactic protein-1 antagonists are also used in controlling blood pressure, endothelial dysfunction and heart failure. Aliskiren, Enalapril and other inhibitors has proved a valuable therapeutic approach in different diseases.
Downloads
References
Atlas S (2007). The Renin-Angiotensin Aldosterone System: Pathophysiological Role and Pharmacologic Inhibition. Journal of Managed Care Pharmacy 13(8) s9-s20.
Balakumar P, Sharma N, Kathuria S, Babbar L and Mahadevan N (2011). Perspectives in Renin-Angiotensin-Aldosterone System Blockade: What’s New? International Journal of Recent Advances in Pharmaceutical Research.1 1-7.
Batlle D, Soler M and Wysocki J (2008). New aspects of the renin–angiotensin system: angiotensinconverting enzyme 2 – a potential target for treatment of hypertension and diabetic nephropathy. Current Opinion in Nephrology and Hypertension.17 250–257.
Berridge N (1945). The Purification and Crystallization of Renin. National Institute for Research in Dairying.39: 179-184.
Bhandari S, Mittal S and Gupta N (2010). Present status of Renin Inhibitors. Medicine Update 20 340-345.
Blumenfeld J, Sealey J, Mann S, Bragat A, Marion R, Pecker M, Sotelo J, August P, Pickering T and Laragh J (1999). β -Adrenergic Receptor Blockade as a Therapeutic Approach for Suppressing the Renin-Angiotensin-Aldosterone System in Normotensive and Hypertensive Subjects. American Journal of Hypertension 12 451–459.
Bonanni L and Vestra M (2012). Oral renin inhibitors in clinical practice: A Perspective Review 3(4) 173-181.
Castrop H, Cherl K, Kurtz A, Schweda F, Todorov V and Wagner C (2010). Physiology of Kidney Renin. American Physiological Society, Physiol Review 90 607–673.
Cody R, and Covit R, Schaer G and Laragh J (1983). Evaluation of a Long-Acting Converting Enzyme Inhibit (Enalapril) for the Treatment of Chronic Congestive Heart Failure. American College of Cardiology.1(4) 1154-1159.
Daniels M, Kenneth V and David M (2007). Treatment of Experimental Myocarditis via Modulation of Renin Angiotensin System. Current Pharmaceutical Design 13 1299-1305.
Fisher N and Hollenbergn (2005). Renin Inhibition: What Are the Therapeutic Opportunities? The American Society of Nephrology 16 592–599.
Hiddo J, Heerspink L (2011). Approaches in Lowering Albuminuria: Travels Along the Renin-Angiotensin-Aldosterone System Pathway. The National Kidney Foundation 18(4) 290-299.
Imanishi T, Goto M and Akasha T (2009). The Renin-Angiotensin-Aldosterone System as a Therapeutic Target for Endothelial Dysfunction. Vascular Disease Prevention 6 65-74. [14]Kurtz A and Wagner CH (1999). Cellular control of renin secretion. The Journal of Experimental Biology 202 219–225.
Meer I, Cravedi P and Remuzzi G (2010). The role of renin angiotensin system inhibition in kidney repair. 3(7) 1-11.
Montori V, Schwartz G, Chapman G, Boerwinkle E and Turner S (2001). Validity of the Aldosterone-Renin Ratio Used to Screen for Primary Aldosteronism.76 877-882.
Moser M, Izzo Jr J and Sica D (2007). The Use of Renin Inhibitors in the Management of Hypertension. The Journal of Clinical Hypertension 9(9) 701-705.
Perez-Rosas, N. and Rodriguez-González J (2011). Pharmacological Modulation of the Renin-Angiotensin System by Mathematical Modeling. Proceedings of the Western Pharmacology Society 54 24-26.
Peti-Peterdi J, Kang J and Toma I (2008). Activation of the renal renin–angiotensin system in diabetes—new concepts. Published by Oxford University 1-4.
Schroten N, Gaillard C, Veldhuisen D, Szymanski M, Hillege H and De Boer R (2012). New roles for renin and prorenin in heart failure and cardiorenal crosstalk 17(2) 191–201.
Sealey J and Laragh J (2007). Aliskiren, the First Renin Inhibitor for Treating Hypertension: Reactive Renin Secretion May Limit Its Effectiveness. American Journal of Hypertension 20 587-597.
Skott O and Jensen B (1993). Cellular and Renal control of Renin secretion.Physiology and Pharmacology.University of Southern Denmark, Odense, Winslowparken 21 1-33.
Sourris K and Forbes J (2012). Diabetic Nephropathy: Current and Novel Therapeutic Approaches to Prevent Its Development and Progression. ISBN 11 180-202.
Turgut F, Balogun A and Abdel-Rahman E (2010). Renin-Angiotensin-Aldosterone System Blockade Effects on the Kidney in the Elderly: Benefits and Limitations. Clinical Journal of American Society Nephrology 5 1330–1339.
Volpe M, Savoia C, Paolis P, Ostrowska B, Tarasi D and Rubattu S (2002). The Renin-Angiotensin System as a Risk Factor and Therapeutic Target for Cardiovascular and Renal Disease. Journal of American Society Nephrology 13 173–S178.
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
editor@ijrasb.com 